Drug Trial Radar · NCT00976378
NOX-A12 First-in-human (FIH) Study
Last checked: Nov 19, 2026Latest source record: Jun 26, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Oct 2009
Primary completion
May 2010
Study completion May 2010
Sponsor
- Lead sponsor
- TME Pharma AGIndustry
- Sponsor type
- Industry
- Collaborators
- German Federal Ministry of Education and Research
- First posted
- Sep 14, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is the first time NOX-A12 will be administered to man. The principal aim of this study is to obtain safety and tolerability data when NOX-A12 is administered by single intravenous (IV) doses to healthy male and female subjects. This information, together with the pharmacokinetic and pharmacodynamic data, will help establish the doses and dosage regimen of administration suitable for subsequent studies in the patient population.
Conditions
- Autologous Stem Cell Transplantation
Interventions
NOX-A12Drug
single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
NOX-A12Drug
single IV dose, at efficacious dose level
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of NOX-A12 by means of adverse events, vital signs, laboratory parameters, 12-lead ECG and immunogenicity assessmentTime frame: 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Scope Life Sciences GmbH
Hamburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.